| Literature DB >> 35527825 |
Ante Miličević1, Goran Šinko1.
Abstract
Acetylcholinesterase (AChE) has proven to be an effective drug target in the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's and dementia. We developed a novel QSAR regression model for estimating potency to inhibit AChE, pK i, on a set of 75 structurally different compounds including oximes, N-hydroxyiminoacetamides, 4-aminoquinolines and flavonoids. Although the model included only three simple descriptors, the valence molecular connectivity index of the zero-order, 0 χv , the number of 10-membered rings (nR10) and the number of hydroxyl groups (nOH), it yielded excellent statistics (r = 0.937, S.E. = 0.51). The stability of the model was evaluated when an initial set of 75 compounds was broadened to 165 compounds in total, with the increase of the range of pK i (exp) from 6.0 to 10.2, yielding r = 0.882 and S.E. = 0.89. The predictive power of the model was evaluated by calculating pK i values for 55 randomly chosen compounds (S.E.test = 0.90) from the calibration model created on other 110 compounds (S.E. = 0.89), all taken from the pool of 165 compounds.Entities:
Keywords: Acetylcholinesterase; Alzheimer's disease; Dementia; Inhibitor; QSAR descriptor
Year: 2022 PMID: 35527825 PMCID: PMC9068751 DOI: 10.1016/j.jsps.2022.01.025
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.562
The values of negative logarithms of the AChE inhibition constant (pKi), and molecular descriptors for 75 compounds. 0χv, nOH and nR10 were calculated by the E-DRAGON program system. The compound names are the same as in the original papers whose references are given.
| No. | Compound | p | 0 | nOH | nR10 |
|---|---|---|---|---|---|
| 1 | ICD-585 | 4.55 | 11.70 | 1 | 0 |
| 2 | HI-6 | 4.51 | 11.40 | 1 | 0 |
| 3 | HLo-7 | 4.62 | 12.79 | 2 | 0 |
| 4 | K027 | 4.14 | 11.70 | 1 | 0 |
| 5 | K048 | 3.96 | 12.41 | 1 | 0 |
| 6 | K033 | 4.77 | 12.39 | 2 | 0 |
| 7 | TMB-4 | 3.74 | 11.68 | 2 | 0 |
| 8 | DMB-4 | 4.00 | 10.98 | 2 | 0 |
| 9 | MMB-4 | 3.31 | 10.27 | 2 | 0 |
| 10 | ICD-692 | 4.74 | 11.99 | 1 | 0 |
| 11 | ICD-467 | 5.92 | 11.53 | 1 | 0 |
| 12 | K114 | 5.68 | 14.29 | 2 | 0 |
| 13 | K127 | 3.76 | 12.81 | 1 | 0 |
| 14 | K203 | 4.44 | 12.15 | 1 | 0 |
| 15 | I | 2.93 | 9.610 | 1 | 0 |
| 16 | II | 3.45 | 14.08 | 1 | 0 |
| 17 | III | 4.31 | 14.93 | 1 | 0 |
| 18 | IV | 3.87 | 15.41 | 2 | 0 |
| 19 | CQ | 4.96 | 7.050 | 0 | 1 |
| 20 | CQ2 | 5.39 | 8.96 | 0 | 1 |
| 21 | TFCQ2 | 5.44 | 9.46 | 0 | 1 |
| 22 | TFCQ8 | 6.34 | 13.70 | 0 | 1 |
| 23 | CQ8 | 6.21 | 13.20 | 0 | 1 |
| 24 | CQAd | 6.11 | 16.77 | 0 | 1 |
| 25 | Chloroquine | 5.40 | 14.53 | 0 | 1 |
| 26 | CQEtOH | 5.00 | 8.83 | 1 | 1 |
| 27 | Galangin | 4.07 | 10.20 | 3 | 1 |
| 28 | Kaempferol | 4.03 | 10.57 | 4 | 1 |
| 29 | Quercitin | 4.42 | 10.94 | 5 | 1 |
| 30 | Myricetin | 4.42 | 11.31 | 6 | 1 |
| 31 | Luteolin | 4.18 | 10.57 | 4 | 1 |
| 32 | Fisetin | 4.00 | 10.57 | 4 | 1 |
| 33 | Apigenin | 3.92 | 10.20 | 3 | 1 |
| 34 | Rutin | 3.52 | 22.29 | 10 | 1 |
| 35 | Metaproterenol | 2.51 | 8.94 | 3 | 0 |
| 36 | Terbutaline | 2.32 | 9.86 | 3 | 0 |
| 37 | Fenoterol | 3.07 | 12.40 | 4 | 0 |
| 38 | Epinephrine | 2.19 | 7.36 | 3 | 0 |
| 39 | Isoproterenol | 2.60 | 8.94 | 3 | 0 |
| 40 | Isoetharine | 3.68 | 10.51 | 3 | 0 |
| 41 | Salbutamol | 2.70 | 10.57 | 3 | 0 |
| 42 | Salmeterol | 4.52 | 17.93 | 3 | 0 |
| 43 | 1 | 3.64 | 12.15 | 3 | 0 |
| 44 | 2 | 3.36 | 12.45 | 3 | 0 |
| 45 | 3 | 3.90 | 13.21 | 3 | 0 |
| 46 | 4 | 4.12 | 14.04 | 3 | 0 |
| 47 | 5 | 3.78 | 13.34 | 3 | 0 |
| 48 | 6 | 3.98 | 13.08 | 3 | 0 |
| 49 | 7 | 4.05 | 13.48 | 3 | 0 |
| 50 | 8 | 3.90 | 13.48 | 3 | 0 |
| 51 | 9 | 3.90 | 15.46 | 3 | 0 |
| 52 | 1a | 7.82 | 23.95 | 1 | 1 |
| 53 | 2a | 8.22 | 24.65 | 1 | 1 |
| 54 | 1b | 8.05 | 24.65 | 1 | 1 |
| 55 | 2b | 7.55 | 25.36 | 1 | 1 |
| 56 | 1c | 7.17 | 25.36 | 1 | 1 |
| 57 | 2c | 7.49 | 26.07 | 1 | 1 |
| 58 | 1d | 6.89 | 23.95 | 1 | 1 |
| 59 | 2d | 7.64 | 24.65 | 1 | 1 |
| 60 | 1e | 7.39 | 24.65 | 1 | 1 |
| 61 | 2e | 7.00 | 25.36 | 1 | 1 |
| 62 | Q1 | 2.42 | 5.96 | 1 | 0 |
| 63 | Q2 | 3.12 | 7.01 | 1 | 0 |
| 64 | Q3 | 3.28 | 8.00 | 1 | 0 |
| 65 | Q4 | 3.26 | 8.71 | 1 | 0 |
| 66 | Q5 | 5.22 | 14.79 | 1 | 0 |
| 67 | Q6 | 3.80 | 10.1 | 1 | 0 |
| 68 | Q7 | 4.49 | 11.99 | 1 | 0 |
| 69 | Q8 | 4.17 | 11.99 | 1 | 0 |
| 70 | Q9 | 4.39 | 11.16 | 1 | 0 |
| 71 | Q10 | 4.04 | 11.16 | 1 | 0 |
| 72 | Q11 | 4.57 | 11.02 | 1 | 0 |
| 73 | Q12 | 3.87 | 11.02 | 1 | 0 |
| 74 | Q13 | 4.74 | 11.29 | 1 | 0 |
| 75 | Q14 | 4.31 | 11.29 | 1 | 0 |
From Ref. (Kovarik et al., 2008).
From Ref. (Šinko et al., 2010).
From Ref. (Maraković et al., 2016).
From Ref. (Bosak et al., 2019).
From Ref. (Katalinić et al., 2010).
From Ref. (Bosak et al., 2017).
From Ref. (Bušić et al., 2016).
From Ref. (Maček Hrvat et al., 2020).
From Ref. (Zandona et al., 2020).
Fig. 1Example of chemical structures of the 10 groups of compounds used in the set of 75 compounds.
Fig. 2Dependence of pKi on the 0χ index for 75 molecules in the set (Table 1). The lines of correlations are made on two subsets of molecules, with (N = 26, r = 0.800) and without (N = 49, r = 0.575) a 10-membered ring. Triangles denote molecules with a 10-membered ring.
Fig. 3Plot of experimental vs. calculated (using Eq. (4)) pKi values; N = 75, r = 0.937, S.E. = 0.51 and S.E.cv = 0.53.
Fig. 4Plot of experimental vs. calculated (using Eq. (4)) pKi (or pIC50) values; N = 165, r = 0.882, rcv = 0.874, S.E. = 0.89 and S.E.cv = 0.91. Circles denote the set of 75 compounds, triangles the set of 56 compounds used in our previous report (Šinko, 2019), and empty circles the set of 34 oximes (Katalinić et al., 2016).
Fig. 5Crystal structure of the human AChE active site (PDB ID 4EY7). Aromatic residues of the peripheral anionic site are orange, of the choline binding site purple, and of the acyl pocket blue. The anti-Alzheimer drug donepezil is yellow. Catalytic Ser203 is represented by a ball and stick. Figure adopted from ref. (Miličević and Šinko, 2021).